Thermosensitive mucoadhesive gel formulation loaded with 5-Fu: Cyclodextrin complex for HPV-induced cervical cancer

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 57, Issue 1-4, 2007, Pages 363-370

  Bilensoy, Erem ^a   Çırpanlı, Yasemin ^a   Şen, Murat ^a   Doğan, A Lale ^a   Çalış, Sema ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

5 Fluorouracil; Cervical cancer; Cyclodextrin; HPV; Hydroxypropyl cyclodextrin; Mucoadhesive; Thermosensitive; Vaginal gel; Cyclodextrin

Indexed keywords

EID: 34047118513     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-006-9259-y     Document Type: Conference Paper

References (37)

1. Bosch, F.X., Manos, M.M., Manoz, N.: Relevance of human papilloma virus in cervical cancer: a worldwide perspective. J. Natl. Cancer Invest. 87, 796-799 (1995)
2. Koutsky, L.: Epidemiology of human papilloma virus infection. Am. J. Med. 102(5A), 3-8 (1997)
3. Lacey, C.J.N.: Therapy for genital human papilloma virus-related disease. J. Clin. Virol. 32S, S82-S90 (2005)
4. Rose, P.G.: Chemoradiotherapy, the new standard care for invasive cervical cancer. Drugs 50(6), 1239-1244 (2000)
5. Parkin, D.M.: Cancer in developing countries. Cancer Surv. 19(20), 519-561 (1994)
6. Gross, G.: Therapy of human papillomavirus infection and associated epithelial tumors. Intervirology 40, 368-377 (1997)
7. Brown, D.R., Schroeder, J.M., Bryan, J.M., Stoler, M.H., Fife, K.H.: detection of multiple human papillomavirus types in condyloma acuminate lesions from otherwise healthy and immunosuppressed patients. J. Clin. Microbiol. 37, 3316-3322 (1999)
8. Walboomers, J.M., Jacobs, M.V., Manos, M.M., Bosch, F.X., Kummer, J.A., Shah, K.V.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-18 (1999)
9. Lacey, C.J.N., Goodall, R., Tennvall, G.T., Maw, R., Kinghorn, G.R., Fisk, P.G.: Randomized controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream and podophyllin in the treatment of genital warts. Sex. Transm. Infect. 79, 270-275 (2003)
10. Snoeck, R., Bossens, M., Parent, D.: Phase II double-blind placebo controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papilloma virus infection. Clin. Infect. Dis. 33, 597-602 (2001)
11. Mansell, P.W.A., Litwin, M.S., Ichinose, H., Krementz, E.T.: Delayed hypersensitivity to 5-fluorouracil following topical chemotherapy of cutaneous cancers. Cancer Res. 35, 1288-1294 (1975)
12. Pall, A., Mahajan, B.B., Puri, K.P.S., Gupta, R.R.: Therapeutic evalulation of intralesional 5% 5-fluorouracil in condyloma acuminata. J. Dermatol. 31, 314-325 (2004)
13. Beutner, K.R., Ferenczy, A.: Therapeutic approaches to genital warts. Am. J. Med. 102(5A), 28-37 (1997)
14. Bonnez, W., Oakes, D., Bailey-Farchione, A.: A randomized double blind placebo controlled trial of systemically administered interferon-α, -β or -γ in combination with cryotherapy for treatment of condyloma acuminate. J. Infect. Dis. 171, 1081-1089 (1995)
15. Garland, S.M., Sellors, J.W., Wikstrom, A.: Imiquimod 5% cream is a safe and effective self-applied treatment for anogential warts-results of an open-label multicentre phase IIIB trial. Int. J. STD AIDS 12, 22-28 (2001)
16. Gollnick, H., Barasso, R., Jappe, U., Ward, K., Eul, A., Carey-Yard, M.: Safety and efficacy of imiquimod 5% cream in the treatment penile warts in uncircumcised men when applied three times (2001)
17. Deshpande, A.A., Rhodes, C.T., Danish, M.: Intravaginal drug delivery. Drug Dev. Ind. Pharm. 18, 1225-1279 (1992)
18. Wolfsson, A.D.: Intravaginal drug delivery technologies. In: Rathbone M, (ed.) Modified-Release Drug Delivery Technology, pp. 759-774. Marcel Dekker, New York (2002)
19. Hardy, E., Jimenes, A.L., de Padua, K.S., Zanewald, L.J.D.: Women's preferences for vaginal antimicrobial contraceptives III. Choice of a formulation, applicator and packaging. Contraception 58, 245-249 (1998)
20. Ceschel, G.C., Maffei, P., Lombardi Borgia S., Ronchi, C., Rossi, S.: (2001) Development of a mucoadhesive dosage form for vaginal administration, Drug Dev. Ind. Pharm. 27(6), 541-547.
21. Chang, J.Y., Oh, Y.K., Choi, H., Kim, Y.B., Kim, C.K.: Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. Int. J. Pharm. 241, 155-163 (2002)
22. Chang, J.Y., Oh, Y.K., Kong, H.S., Kim, E.J., Jang, D.D., Nam, K.T., Kim, C.K. Prolonged antifungal effects of clotrimazole-containing mucoadhesive thermosensitive gels in vaginitis. J. Controlled Rel. 82, 39-50 (2002)
23. Chu, J.S., Amidon, G.L., Weiner, N.D., Goldberg, A.H.: Mixture experimental design in the development of a mucoadhesive gel formulation. Pharm. Res. 8, 1401-1407 (1991)
24. Park, H., Robinson, J.R.: Physicochemical properties of water insoluble polymers important to mucin/epithelial adhesion. J. Controlled Rel. 2, 42-57 (1985)
25. Veyries, M.L., Couarrazze, G., Geiger, S., Agnely, F., Massias, L., Kunzli, B., Faurisson, R., Rouveix, B.: Controlled release of vancomycin from poloxamer 407 gels. Int. J. Pharm. 192, 183-193 (1999)
26. Desai, S.D., Blanchard, J.: Pluronic F127 based ocular delivery system containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine. Drug Deliv. 7, 201-207 (2000)
27. Bochot, A., Fattal, E., Grossiord, J.L., Puisieux, F., Couvreur, P.: Characterization of a new ocular delivery system based on a dispersion of liposomes in a thermosensitive gel. Int. J. Pharm. 162, 119-127 (1998)
28. Kim, E.Y., Gao, Z.G., Park, J.S., Li, H., Han, K.: rhEGF/HP-β-CD complex in poloxamer gel for ophthalmic delivery. Int. J. Pharm. 233, 159-167 (2002)
29. Thompson, D.O.: Cyclodextrins as enabling excipients: their present and future use in pharmaceuticals. CRC Crit. Rev. Ther. Drug Carrier Syst. 14(1), 1-104 (1997)
30. Loftsson, T., Brewster, M.E.: Pharmaceutical applications of cyclodextrins I Drug solubilization and stabilization. J. Pharm. Sci. 85(10), 1017-1025 (1996)
31. Yashida, A., Yamamoto, M., Irie, T., Hirayama, F., Uekama, K.: Some pharmaceutical properties of 3-hydroxypropyl and 2,3-dihydroxypropyl β-cyclodextrins and their solubilizing and stabilizing ability. Chem. Pharm. Bull. 37, 1059-1063 (1989)
32. Hedges, A.R.: Industrial applications of cyclodextrins. Chem. Rev. 98, 2035-2044 (1998)
33. Choi, H.G., Jung, J.H., Ryu, J.M., Yoon, S.J., Oh, Y.K., Kim, C.K.: Development of in situ gelling and mucoadhesive acetaminophen liquid suppository. Int. J. Pharm. 165, 33-44 (1998)
34. Miyazaki, S., Nakamura, T., Takada, M.: Thermo-sensitive sol-gel transition of Pluronic F-127. Yakuzaigaku 51, 36-43 (1991)
35. Blanco-Fuente, H., Esteban-Fernandez, B., Blanco-Mendez, J., Otero-Espinar, F.J.: Use of β-cyclodextrins to prevent modifications of the properties of carbopol hydrogels due to carbopol-drug interactions, Chem. Pharm. Bull. 50(1), 40-46 (2002)
36. Boulmedarat, L., Grossiord, J.L., Fattal, E., Bochot, A.: Influence of methyl β-cyclodextrin and liposomes on rheological properties of Carbopol®974 NF gels. Int. J. Pharm. 254, 59-64 (2003)
37. Anderson, B.C., Pandit, N.K., Mallapragada, S.: Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b- poly(ethylene oxide) gels. J. Controlled Rel. 70, 157-167 (2001)